"The growth trajectory of canned infant formula has continued with total consumer packaged volumes almost tripling from the same period last year and up 36 percent on the second half of last year," Penno said. "We have also renegotiated our supply agreements with New Hope Nutritionals and with Bright Dairy, which provides for four-fold volume growth over a five-year period. However, we don't expect this to impact sales until FY19."
In the six month period Synlait has invested $34.5 million in capital expenditure throughout New Zealand. The major components were the Synlait Auckland blending and canning facility, where it spent $11.2 million, and the new wetmix kitchen at Synlait Dunsandel, which cost $18.4 million. Synlait also established a new research and development centre in Palmerston North.
"Both of these projects are critical for keeping up with customer demand, and give us the ability to expand on our infant formula business," said Penno.
He also said that Synlait's cash flow generation of $204.3 million for the 12 months to Jan. 31 has fully funded the capital expenditure program and has enabled the reduction of debt to low levels.
Total net debt for in the first half of the year was $49.7 million, down from $147 million in the same period a year earlier.
"This leaves the company well placed to fund our expansion plans. At Synlait Dunsandel we expect to spend $125 million on an advanced liquid dairy packaging facility, and at Synlait Pokeno we will spend $260 million to establish our new nutritional powder manufacturing facility," said chairman Graeme Milne.
Penno also said that Synlait's full-year spend on research and development is forecast at $7 million versus $4.75 million in the prior year. "We intend to lift this to 1.5 percent of revenue within the next few years, which will see it double again."
The stock last traded at $8.09 and is up 132 percent over the past 12 months.